Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Reckitt beats like-for-like sales estimates, driven by Dettol, Lysol

Published 24/04/2024, 07:19
© Reuters. FILE PHOTO: Lysol, a brand of Reckitt Benckiser Group PLC, is seen on display in a store in Manhattan, New York City, U.S., March 24, 2022. REUTERS/Andrew Kelly/File Photo

By Richa Naidu and Agata Rybska

LONDON (Reuters) - Consumer goods group Reckitt's like-for-like sales growth beat estimates in the first quarter as more people bought its Lysol, Dettol and Finish cleaning products even as prices rose, it said in a trading update on Wednesday.

Shares in Reckitt were up nearly 6% in morning trade.

The company also reiterated that it faces "contingent liabilities" - a term used for those dependent on future events - from a product liability suit filed against its Mead Johnson infant formula business in the United States.

An Illinois jury in March ordered Mead Johnson to pay $60 million to the mother of a premature baby who died of an intestinal disease after being fed the company's Enfamil Premature 24 baby formula. Mead Johnson said in March it would appeal the verdict.

"It's a complex litigation. It's early stages," CEO Kris Licht said in a call with journalists.

The company said it was on track to meet full-year revenue and profit targets, led by mid single-digit growth across its health and hygiene businesses.

"We could expect the share price to outperform peers today, somewhat constrained by the ongoing litigation uncertainty," Jefferies analyst David Hayes said.

Reckitt's quarterly like-for-like net sales rose 1.5%, against a 0.9% decline expected by analysts in a poll by the company.

"We continue to benefit from carryover pricing and consumers trading up to our premium innovations," Licht said.

Consumer companies from Reckitt to Nestle have invested heavily in product innovation to win back shoppers who had turned to cheaper brands during the COVID-19 pandemic and more recent cost-of-living crisis.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

They hope improvements to existing products will allow them to raise prices without taking a hit on sales volumes.

Reckitt's other products include Nurofen tablets, cold remedy Lemsip and Durex condoms.

The company said first-quarter volumes rose 2.9% at the company's hygiene business - its largest by revenue - but the price/mix metric that shows how much its products sold for rose by 4.2%.

Its overall price/mix ratio rose 2% while volumes declined by 0.5%. Analysts had expected a 2.2% price/mix gain and volumes to decrease by 3.2%.

(This story has been corrected to say that analysts had expected a 0.9% decline in like-for-like net sales, not an increase, in paragraph 8)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.